Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; balance assessment systems to evaluate patients with balance disorders. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was founded in 1987 and is headquartered in Pleasanton, California.
IPO Year:
Exchange: NASDAQ
Website: natus.com
15-12G - NATUS MEDICAL INC (0000878526) (Filer)
EFFECT - NATUS MEDICAL INC (0000878526) (Filer)
EFFECT - NATUS MEDICAL INC (0000878526) (Filer)
EFFECT - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
POS AM - NATUS MEDICAL INC (0000878526) (Filer)
SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc
Thomas J. Sullivan Appointed President & Chief Executive Officer No Change To 4th Quarter Guidance PLEASANTON, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointment of Thomas J. Sullivan as President & Chief Executive Officer effective December 27, 2021 and a focus on long-term growth. Earlier this year, the Board of Directors engaged a strategic consulting firm to assist it in developing a strategy to build upon Natus' market leading p
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)
SC 13G - NATUS MEDICAL INC (0000878526) (Subject)
SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)
SC 13G - NATUS MEDICAL INC (0000878526) (Subject)
MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue
Highlights: • Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value• Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry for app
PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domes
Q4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47 PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months and full year ended December 31, 2021. For the fo
PLEASANTON, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 fourth quarter financial results after the close of the market on Thursday, February 24th. Natus management will host a conference call on Friday, February 25th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 f
Q3-2021 Key ResultsRevenue (millions)$113.9 • Revenue increased 11% compared to Q3 2020GAAP EPS$0.16 • Generated $7.1 million in operating cash flowNon-GAAP EPS$0.28 PLEASANTON, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three and nine months ended September 30, 2021. For the third quarter ended September 30, 2021, the Company reported revenue of $113.9 million, an i
PLEASANTON, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 third quarter financial results after the close of the market on Thursday, November 4th. Natus management will host a conference call on Friday, November 5th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 fo
Q2-2021 Key ResultsRevenue (millions)$116.0 • Revenue increased 37% compared to Q2 2020• Generated $19.4 million in operating cash flow• GAAP and Non-GAAP EPS increased by $0.36 and $0.42, respectively compared to Q2 2020GAAP EPS$0.10 Non-GAAP EPS$0.29 PLEASANTON, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three and six months ended June 30, 2021. For the second quarter ended June 30, 2021, the Company reported revenue
SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc
NEW YORK, July 21, 2022 /PRNewswire/ -- Novanta Inc. (NASD: NOVT) will replace Six Flags Entertainment Corp. (NYSE:SIX) in the S&P MidCap 400, and Six Flags will replace Natus Medical Inc. (NASD: NTUS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 26. ArchiMed acquired Natus Medical in a deal that closed today. Six Flags Entertainment is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 26, 2022 S&P MidCap 400 Addition Novanta NOVT Information Technology S&P MidCap 400
MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue
Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22 MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months ended March 31, 2022. For the first quarter ended March 31, 2022, the Company reported revenue of $119.8 million, an increase of 4.2% compared to $114.9 million reported for the fir
Highlights: • Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value• Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry for app
PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domes
Q4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47 PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months and full year ended December 31, 2021. For the fo
PLEASANTON, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced preliminary 2021 fourth quarter and full year revenue. The Company expects to report revenue of approximately $127.5 to $128.5 million for the fourth quarter of 2021, and full year 2021 of $472.3 to $473.3 million. "We are pleased with the high single digit revenue growth delivered by our Natus Teammates in the fourth quarter despite supply chain constraints impacting the cost of logistics and
PLEASANTON, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that Thomas J. Sullivan, President and Chief Executive Officer, and Drew Davies, Executive Vice President and Chief Financial Officer, will be presenting at the 24th Annual Needham Virtual Growth Conference from 2:00 PM to 2:40 PM ET on Friday, January 14th. In addition, Mr. Sullivan and Mr. Davies will also host one-on-one meetings during the day with institutional investors. Investors interes
PLEASANTON, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 fourth quarter financial results after the close of the market on Thursday, February 24th. Natus management will host a conference call on Friday, February 25th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 f
Novanta Inc (NASDAQ:NOVT) braces to replace Six Flags Entertainment Corp (NYSE:SIX) in the S&P MidCap 400 effective before trading on July 26. Six Flags will replace Natus Medical Inc (NASDAQ:NTUS) in the S&P SmallCap 600. ArchiMed snapped Natus Medical in a deal that closed today. Novanta clocked 26% revenue growth to $204.2 million in the first quarter of FY22, beating the consensus of $196.1 million. Adjusted EPS of $0.73 beat the consensus of $0.63. Price Action: NOVT shares traded higher by 9.74% at $150.25 in the premarket on the last check Friday.
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20220721-1454377/1454377_6ntus.pdf
Natus Medical (NASDAQ:NTUS) reported quarterly earnings of $0.22 per share which missed the analyst consensus estimate of $0.26 by 15.38 percent. This is a 37.5 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $119.80 million which beat the analyst consensus estimate of $115.70 million by 3.54 percent. This is a 4.24 percent increase over sales of $114.93 million the same period last year.
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million. • Bluegreen Vacations (NYSE:BVH) is estimated to report quarterly earnings at $0.53 per share on revenue of $181.17 million. • Selecta Biosciences (NASDAQ:SELB) is expected to report quarterly loss at $0.11 per share on revenue of $13.12 million. • Alpha Metallurgical (NYSE:AMR) is projected to report quarterly earnings at $19.04 per share on revenue of $944.95 million. • DigitalBridge Group (NYSE:DBRG) is projected to report quarterly loss at $0.03 per share on revenue of $259.60 million. • Madison Square Garden (NYSE:MSGS) i
Gainers Casa Systems, Inc. (NASDAQ:CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core network functions. Enservco Corporation (NASDAQ:ENSV) climbed 38% to settle at $3.63 on Monday. Enservco delayed filing of Form 10-K to restate 2021 Form 10-Qs to account for company's utilization of deferred tax liabilities. Frequency Therapeutics, Inc. (NASDAQ:FREQ) gained 30.8% to close at $1.91 on above-average volume. Natus Medical Incorporated (NASDAQ:NTUS) rose 28.6% to close at $33.51 after the company announced it will be acquired by ArchiMed Group for $33.50 per share in cash. BitNile Holdings, Inc. (NYSE
U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday. The Dow traded up 0.17% to 34,511 while the NASDAQ rose 0.26% to 13,385.50. The S&P also rose, gaining, 0.26% to 4,403.81. Also check this: 4 Stocks Under $5 Insiders Are Aggressively Buying Leading and Lagging Sectors Energy shares jumped by 1.9% on Monday. Meanwhile, top gainers in the sector included Camber Energy, Inc. (NYSE:CEI), up 19% and PHX Minerals Inc. (NYSE:PHX) up 9%. In trading on Monday, health care shares fell 0.8%. Top Headline Bank of America Corp (NYSE:BAC) reported better-than-expected results for its first quarter. The bank repo
Gainers Natus Medical (NASDAQ:NTUS) shares rose 28.8% to $33.55 during Monday's regular session. The current volume of 3.0 million shares is 2073.2% of Natus Medical's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.1 billion. Frequency Therapeutics (NASDAQ:FREQ) stock moved upwards by 27.39% to $1.86. As of 13:30 EST, this security is trading at a volume of 4.8 million shares, making up 1239.5% of its average full-day volume over the last 100 days. The company's market cap stands at $65.0 million. Imara (NASDAQ:IMRA) stock rose 16.34% to $1.21. The current volume of 1.6 million shares is 443.0% of Imara's average full
U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. Following the market opening Monday, the Dow traded down 0.39% to 34,317.66 while the NASDAQ fell 0.93% to 13,226.95. The S&P also fell, dropping, 0.47% to 4,372.00. Also check this: 4 Stocks Under $5 Insiders Are Aggressively Buying Leading and Lagging Sectors Energy shares jumped by 1.1% on Monday. Meanwhile, top gainers in the sector included Camber Energy, Inc. (NYSE:CEI), up 22% and San Juan Basin Royalty Trust (NYSE:SJT) up 12%. In trading on Monday, health care shares fell 0.9%. Top Headline Bank of America Corp (NYSE:BAC) reported better-than-expected resu
Gainers Casa Systems, Inc. (NASDAQ:CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions. Natus Medical Incorporated (NASDAQ:NTUS) gained 28.7% to $33.53 after the company announced it will be acquired by ArchiMed Group for $33.50 per share in cash. Forge Global Holdings, Inc. (NYSE:FRGE) jumped 25% to $16.99. Forge Global Holdings named James H. Herbert, II to its Board of Directors, effective as of April 12. AgriFORCE Growing Systems, Ltd. (NASDAQ:AGRI) shares gained 21.3% to $2.6798. BitNile Holdings, Inc. (NYSE:NILE) rose 17% to $0.6436 following a 5% decline on Thursday. Camber Energy, Inc. (NY
U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday. Following the market opening Monday, the Dow traded up 0.29% to 34,550.93 while the NASDAQ rose 0.38% to 13,401.15. The S&P also rose, gaining, 0.30% to 4,405.72. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Energy shares jumped by 0.9% on Monday. Meanwhile, top gainers in the sector included Camber Energy, Inc. (NYSE:CEI), up 17% and Hallador Energy Company (NASDAQ:HNRG) up 12%. In trading on Monday, health care shares fell 0.8%. Top Headline Bank of America Corp (NYSE:BAC) reported better-than-expected results for its first quarter.